As of 2024-12-13, the Intrinsic Value of Helix Biopharma Corp (HBP.TO) is
-0.94 CAD. This HBP.TO valuation is based on the model Peter Lynch Fair Value.
With the current market price of 0.87 CAD, the upside of Helix Biopharma Corp is
-208.62%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
-0.94 CAD
Intrinsic Value
HBP.TO Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| Fair Value |
-0.94 - -0.94 |
-0.94 |
-208.62% |
| P/E |
(0.02) - (0.06) |
(0.02) |
-102.2% |
| DDM - Stable |
(1.97) - (14.91) |
(8.44) |
-1070.2% |
| DDM - Multi |
(0.67) - (4.08) |
(1.16) |
-233.5% |
HBP.TO Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
42.65 |
| Beta |
1.45 |
| Outstanding shares (mil) |
49.02 |
| Enterprise Value (mil) |
41.57 |
| Market risk premium |
5.10% |
| Cost of Equity |
7.93% |
| Cost of Debt |
5.00% |
| WACC |
5.81% |